Comparative Pharmacology
Head-to-head clinical analysis: IRBESARTAN versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IRBESARTAN versus TEVETEN HCT.
IRBESARTAN vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irbesartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, thereby blocking vasoconstriction and aldosterone secretion.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
150 mg orally once daily; may increase to 300 mg once daily if needed.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Clinical Note
moderateIrbesartan + Benzydamine
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine."
Clinical Note
moderateIrbesartan + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Irbesartan."
Clinical Note
moderateIrbesartan + Droxicam
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam."
Clinical Note
moderateIrbesartan + Loxoprofen
The terminal elimination half-life of irbesartan is 11–15 hours, supporting once-daily dosing.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Irbesartan is primarily eliminated via biliary/fecal excretion (approximately 80%) and renal excretion (approximately 20%).
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen."